Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 7710 results

  1. Intermittent urethral catheters for long-term urinary management in adults : Late Stage Assessment

    In development [GID-HTE10049] Expected publication date: 17 June 2025

  2. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082

    In development [GID-TA10969] Expected publication date: TBC

  3. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 03 September 2025

  4. Kidney Cancer

    In development [GID-QS10186] Expected publication date: TBC

  5. Abortion Care

    In development [GID-NG10433] Expected publication date: TBC

  6. Fertility problems: assessment and treatment

    In development [GID-NG10263] Expected publication date: 06 August 2025

  7. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development [GID-TA11545] Expected publication date: 05 November 2025

  8. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025

  9. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: TBC

  10. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

  11. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

  12. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]

    In development [GID-TA10959] Expected publication date: 20 August 2025

  13. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

    In development [GID-TA11512] Expected publication date: 16 April 2025

  14. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

  15. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025